Contact Us

If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

You can contact us by phone, fax, or email, or by filling out the form below.

Are you a patient with a question?
Consumer Affairs
Phone: 1-888-508-6978
Fax: 610-290-9729
Email: cslb-consumeraffairs@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Are you a healthcare professional with a product-related question?
Medical Information
Phone: 1-800-504-5434
Fax: 610-878-4550
Email: medinfona@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Would you like to report an undesirable effect with use of a CSL Behring product?
If you experience any undesirable side effect(s) with a CSL Behring product, talk to your doctor, pharmacist, or nurse. If you would like to report the side effect(s) to CSL Behring, please contact us at:
CSL Behring US Pharmacovigilance
Phone: 1-866-915-6958
Email: Adverse.Events.Global@cslbehring.com
(Available 24 hrs/day)
You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Do you have a media-related question or comment?
Corporate Media Inquiries
Chris Florentz
Phone: 610-878-4316
Fax: 610-290-9316
Product-Related Media Inquiries
Anthony Farina
Phone: 610-878-4665
Fax: 610-290-9665
(Standard business hours are 8:30 am - 5:00 pm ET)
For all other questions, please contact...
CSL Behring Headquarters, North America
Phone: 610-878-4000
Fax: 610-878-4009
Address:

PO Box 61501
1020 First Avenue
King of Prussia, PA 19406-0901 USA

(Standard business hours are 8:30 am - 5:00 pm ET)

Comments/Inquiries Form

Type the verification text in the box below:

Verification Word
By submitting this form, you are consenting to receive an email response with relevant information from CSL Behring. You may also receive relevant information from CSL Behring in the future. You will have the ability to opt out from receiving CSL Behring emails or mailings at any time. View our Privacy Policy here.
MTL14-07-0006 09/2014
Expand

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin products, including Hizentra. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.

For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. See full prescribing information for complete boxed warning.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Monitor patients for aseptic meningitis syndrome (AMS), which has been reported with SCIg. In patients at risk of acute renal failure, monitor renal function, including blood urea nitrogen, serum creatinine and urine output. Also monitor patients for clinical signs of hemolysis or transfusion-related acute lung injury (TRALI).

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritus, vomiting, upper abdominal pain, migraine and pain.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra including boxed warning.

Collapse
Professionals Contact Us
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2015 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ10-12-0023(1) 1/2015